慢性阻塞性肺病
医学
支气管扩张剂
重症监护医学
罗氟司特
哮喘
药理学
免疫学
内科学
作者
Lveli Wang,Chuang Xiao,Yaping Liang,Zhiying Weng,Weimin Ye
出处
期刊:Nano LIFE
[World Scientific]
日期:2021-09-01
卷期号:11 (03): 2140008-2140008
被引量:4
标识
DOI:10.1142/s1793984421400080
摘要
Chronic obstructive pulmonary disease (COPD) is the third-most deadly disease in the world and will be a major healthcare problem for decades to come. Its etiology is mainly related to the exposure to cigarette smoke and poisonous gases, and the infections of viruses including COVID-19 induce acute exacerbation of COPD, which may cause death in patients. Few advances have been made in COPD pathological mechanism, and the current clinical treatment strategies focus on both bronchodilator and anti-inflammatory interventions; but with limited clinical therapeutic agents, COPD therapies still lack more drugs especially those that antagonize COPD-specific inflammatory responses. We review the COPD clinically applied drugs, and the progress of research on new drugs and related novel targets, including [Formula: see text] agonists and anti-muscarinic drugs for airway diastole, glucocorticoids and phosphodiesterase-4 inhibitors for anti-inflammatory, protease inhibitors, emerging antioxidants, adhesion factor inhibitors, growth factor antagonists, adenylate cyclase agonists, chemokine antagonists, etc. We thus provide insights on the COPD new drugs research and development.
科研通智能强力驱动
Strongly Powered by AbleSci AI